As seen on Global Drug researcher disputes rare disease medication pricing
Drug researcher disputes rare disease medication pricing.
HOW MUCH LONGER WILL SMA PATIENTS HAVE TO WAIT TO GET THE APPROVED TREATMENT?
If it were not for bad news, the spinal muscular atrophy (SMA) community in Canada would have no news at all. At least in the past couple of…
Progress Needed to Help Canadians affected with SMA
Cure SMA Canada urges timely, committed negotiations to provide coverage of first-ever and life-saving treatment for debilitating childhood disease. Cure SMA Canada, on behalf of Canadians diagnosed with Spinal Muscular…
Progress Needed to Help Canadians affected with SMA
Cure SMA Canada urges timely, committed negotiations to provide coverage of first-ever and life-saving treatment for debilitating childhood disease Cure SMA Canada, on behalf of Canadians diagnosed with…
Canadian drug approuval and funding process
Clinical Trials Clinical trials test drug candidates for safety and effectiveness. Clinical Trial Basics A clinical trial, also called an interventional study, tests new drugs and treatments. It can…
Latest advancements
The Cure SMA drug pipeline is one of the primary ways we evaluate the success of our research program. The pipeline identifies the major drug programs in development, and tracks…
Community update January 4, 2018
Dear Canadian SMA Community and its supporters, Before the Christmas holidays, our community received a shocking response from CDEC (Canadian Drug Expert Committee) of only recommending reimbursement of a small…
Biogen Community Update – December 22, 2017
Biogen Community Update – December 22, 2017 Dear members of the SMA community, In response to your request for information, we would like to provide you with an update on…
BIOGEN RESPONDS TO COVERAGE RECOMMENDATION BY THE CANADIAN DRUG EXPERT COMMITTEE (CDEC) FOR SPINRAZA, THE ONLY TREATMENT APPROVED FOR TREATMENT OF 5Q SPINAL MUSCULAR ATROPHY (SMA)
BIOGEN RESPONDS TO COVERAGE RECOMMENDATION BY THE CANADIAN DRUG EXPERT COMMITTEE (CDEC) FOR SPINRAZA, THE ONLY TREATMENT APPROVED FOR TREATMENT OF 5Q SPINAL MUSCULAR ATROPHY (SMA) Ottawa – December 22,…